Although an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, bevacizumab, demonstrated partial tumor regression in 41% and improved hearing in 20% of NF2 patients, its chronic use is limited by renal toxicity [8]. The gene discussed is NF2; the disease is neoplasm.